Search Results for "added benefit assessment"

Michael Pietrack

Leading From the Front: 3 Leadership Lessons From Mark Cuban

Dec 17^th • 6 mins read

Michael Pietrack

Managing Emotions After Being Downsized

Oct 21^st • 5 mins read

Michael Pietrack

The Four Employment Agreement Questions Every Pharma Executive Must Ask

Dec 18^th • 6 mins read

Tom Caravela

12 Interview Techniques to Help Land Your Next Job

May 12^th • 1 min read

Tom Caravela

“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

Jul 9^th • 1 min read

Tom Caravela

MSL Retention – What Matters Most

Mar 15^th • 2 mins read

Tom Caravela

10 Ways to Make an Impact on a Phone Interview

Apr 9^th • 1 min read

Tom Caravela

Resume Writing and Editing Tips for Pharma Professionals

Aug 8^th • 1 min read

Bridget Rasmusson

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Oct 12^th • 1 min read

Tom Caravela

7 High-Cost Interview Mistakes that are Easy to Avoid

Jul 28^th • 1 min read

Tom Caravela

INTENTION: The Key to Achieving Your Goals

Jan 21^st • 1 min read

Tom Caravela

Promotability: How to Land Your Next Promotion

May 5^th • 10 mins read

Bridget Rasmusson

Positioning Yourself to Become an MSL in 2022

Dec 21^st • 10 mins read

iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%

Sep 3^rd • 1 min read

iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

May 16^th • 5 mins read

B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Apr 20^th • 8 mins read

Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7^th • 12 mins read

Adela Rodriguez, Francis Esposito, Helena Oliveres, Ferran Torres and Joan Maurel

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Feb 11^th • 3 mins read

Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23^rd • 8 mins read

Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Feb 22^nd • 10 mins read

Navigation

Results for 'added benefit assessment'

Leading From the Front: 3 Leadership Lessons From Mark Cuban

Managing Emotions After Being Downsized

The Four Employment Agreement Questions Every Pharma Executive Must Ask

12 Interview Techniques to Help Land Your Next Job

“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

MSL Retention – What Matters Most

10 Ways to Make an Impact on a Phone Interview

Resume Writing and Editing Tips for Pharma Professionals

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

7 High-Cost Interview Mistakes that are Easy to Avoid

INTENTION: The Key to Achieving Your Goals

Promotability: How to Land Your Next Promotion

Positioning Yourself to Become an MSL in 2022

Clinical Educator Oncology Program Improves Adherence by 29%

Transforming oncology: Five frontiers driving progress in cancer care

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Related Topics

Navigation

Results for 'added benefit assessment'

Leading From the Front: 3 Leadership Lessons From Mark Cuban

Managing Emotions After Being Downsized

The Four Employment Agreement Questions Every Pharma Executive Must Ask

12 Interview Techniques to Help Land Your Next Job

“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

MSL Retention – What Matters Most

10 Ways to Make an Impact on a Phone Interview

Resume Writing and Editing Tips for Pharma Professionals

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

7 High-Cost Interview Mistakes that are Easy to Avoid

INTENTION: The Key to Achieving Your Goals

Promotability: How to Land Your Next Promotion

Positioning Yourself to Become an MSL in 2022

Clinical Educator Oncology Program Improves Adherence by 29%​

Transforming oncology: Five frontiers driving progress in cancer care

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Related Topics

Clinical Educator Oncology Program Improves Adherence by 29%